HK inno.N Corporation

195940 KRX Pharmaceuticals Pharmaceuticals
KOSDAQ
₩40,700.00
+0.99%
Delayed · cached 15 min

Fair value analysis

195940
HK inno.N Corporation
PharmaceuticalsPharmaceuticals
₩40,700.00
Close used for this calculation
₩16,592.53Fair value
Financial DNA Score
Profitability · Returns · Balance Sheet · Efficiency · Growth
21/100
Profitability4/25
Returns1/25
Balance Sheet12/25
Efficiency4/25
Growth0/25
Weak
Quality radar
21Prof.4/25Ret.1/25Eff.4/25B.Sht12/25Growth0/25

Consensus fair value

₩16,592.53
Above FV
▼ -59.2% against the close used
Model range ₩1,763.62 – ₩27,718.48
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear₩1,763.62Fair value₩16,592.53Bull₩27,718.48
FairClose
52-week traded range
52W low ₩34,900.0052W high ₩57,600.00

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading above the consensus fair value

HK inno.N Corporation closed at ₩40,700.00, 145.3% above the consensus fair value of ₩16,592.53 drawn from 7 valuation models.

Financial DNA score 21/100 — Weak. P/E of 47.6x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation
₩1,763.62
-95.7%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=8%, r=10%, tg=3%, n=10yr
Graham Number
₩27,718.48
-31.9%
√(22.5 × EPS × BVPS)
EPS=855.78, BVPS=39901.96 · outside Graham range (P/E 47.6, P/B 1) — asset-light, treat as a rough floor
P/E Fair Value
₩17,115.60
-57.9%
EPS × 20x (sector P/E)
EPS=855.78, Sector P/E=20x
EV/EBITDA
₩5,078.23
-87.5%
(EBITDA × 10x − Net Debt) ÷ Shares
EBITDA=50.32B
Book Value (P/B)
₩8,578.92
-78.9%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=39901.96, ROE=2.2%, g=3%, r=10%
Reverse DCF
₩40,700.00
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 18.8% | Historical: 0%
Margin of Safety
₩11,649.43
-71.4%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=15532.57, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Educational data only. Not a recommendation to buy, sell or hold any security.